Dalpiciclib 100mg

DRUG3 trials

Sponsors

West China Hospital, Fujian Cancer Hospital

Conditions

Breast DiseasesBreast NeoplasmsCDK4/6 InhibitorDalpiciclibEndocrine Breast DiseasesEsophageal Squamous Cell CarcinomaHR+/HER2- Breast CancerHead and Neck Squamous Cell Carcinoma

Phase 1

Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas

RecruitingNCT06109207

West China HospitalHead and Neck Squamous Cell Carcinoma

Start: 2023-10-31End: 2025-10-31Target: 6Updated: 2024-07-23

Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas

RecruitingNCT06225921

West China HospitalEsophageal Squamous Cell Carcinoma

Start: 2023-12-29End: 2025-01-15Target: 6Updated: 2024-03-06

Phase 2

Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study

RecruitingNCT07581834

Fujian Cancer HospitalBreast Diseases, Breast Neoplasms, CDK4/6 Inhibitor +3

Start: 2026-01-21End: 2032-06-30Target: 2000Updated: 2026-05-12